Instil Bio Inc (TIL) Stock Price, Quote & News

Company Profile

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer. The company also conducts a Phase 1 open label trial in China for AXN-2510/IMM2510 as monotherapy in patients with advanced solid tumors, including triple-negative breast cancer, squamous...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 499 3350

Website: instilbio.com

Address:

3963 Maple Avenue, Suite 350, Dallas, United States

Magic8BallResponse Jul. 31 at 1:12 PM

$TIL Due for an upgrade

0 · Reply

OpenOutcrier Jul. 31 at 11:37 AM

$TIL (+2.0% pre) ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in https://ooc.bz/l/72030

0 · Reply

BigSqueezeComing Jul. 31 at 10:39 AM

$TIL ImmuneOnco expects to present updated safety and efficacy data at a forthcoming medical conference. Plans include advancing IMM2510/AXN‑2510 into Phase 3 studies in China.

0 · Reply

BigSqueezeComing Jul. 31 at 10:38 AM

$TIL 33 patients received 10 mg/kg of IMM2510. • 21 patients had at least one tumor assessment and were considered efficacy-evaluable. • Among evaluable patients, the overall partial response rate (PRR) was 62%. Breakdown by subtype: • 80% PRR in squamous NSCLC (8/10 patients) • 46% PRR in non‑squamous NSCLC (5/11 patients

0 · Reply

BigSqueezeComing Jul. 31 at 10:38 AM

$TIL took profit

0 · Reply

BigSqueezeComing Jul. 31 at 10:36 AM

$TIL going higher

0 · Reply

BigSqueezeComing Jul. 31 at 10:19 AM

$TIL pt 30+

0 · Reply

BigSqueezeComing Jul. 31 at 10:10 AM

$TIL ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China By Instil Bio | July 31, 2025, 6:00 AM

0 · Reply

NVDAMillionaire Jul. 29 at 7:18 PM

$TIL Excellent article that nails exactly where TIL stands right now. So if you want to update your TIL knowledge or get acquainted with TIL, this is a must read. https://beyondspx.com/article/instil-bio-a-strategic-pivot-towards-bispecific-antibodies-nasdaq-til

0 · Reply

Doozio Jul. 27 at 9:38 PM

Wait $TIL the huckleberries arrive n they give a 🪧 during 🐒🍌🧠⏰♾️

0 · Reply

ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China

$Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors$

Jul 2, 2025, 6:00 AM EDT - 5 weeks ago

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

Jun 11, 2025, 7:00 AM EDT - 2 months ago

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

Jun 2, 2025, 7:00 AM EDT - 2 months ago

Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer

May 30, 2025, 7:00 AM EDT - 2 months ago

Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference

May 25, 2025, 7:09 AM EDT - 2 months ago

Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success

May 23, 2025, 7:00 AM EDT - 2 months ago

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago

May 22, 2025, 6:00 AM EDT - 2 months ago

Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025

May 13, 2025, 7:00 AM EDT - 3 months ago

Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mar 4, 2025, 7:09 AM EST - 5 months ago

Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Jan 14, 2025, 7:00 AM EST - 7 months ago

Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody

Jan 7, 2025, 2:06 PM EST - 7 months ago

Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside

Dec 1, 2024, 5:00 AM EST - 8 months ago

Instil Bio's Strategic Shift To SYN-2510: A Speculative 'Buy' Opportunity

Sep 16, 2024, 12:31 PM EDT - 11 months ago

Crude Oil Surges Over 1%; Instil Bio Shares Plunge

Sep 16, 2024, 6:00 AM EDT - 11 months ago

Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer

Sep 13, 2024, 1:22 PM EDT - 11 months ago

Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements

Aug 13, 2024, 5:00 PM EDT - 1 year ago

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 1, 2024, 6:00 AM EDT - 1 year ago

Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

May 10, 2024, 7:00 AM EDT - 1 year ago

Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mar 21, 2024, 5:00 PM EDT - 1 year ago

Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Jan 16, 2024, 8:00 AM EST - 1 year ago

Instil Bio Announces Strategic Update

Dec 5, 2023, 5:00 PM EST - 1 year ago

Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split

Nov 13, 2023, 5:00 PM EST - 1 year ago

Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 6, 2023, 7:00 AM EST - 1 year ago

Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jun 26, 2023, 4:38 PM EDT - 2 years ago

Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference

May 11, 2023, 7:00 AM EDT - 2 years ago

Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update

Mar 31, 2023, 7:00 AM EDT - 2 years ago

Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Jan 31, 2023, 5:00 PM EST - 2 years ago

Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site

Jan 18, 2023, 1:58 PM EST - 2 years ago

7 Cheap But Risky Biotech Stocks

BCAB IMRX NKTX

Jan 9, 2023, 7:00 AM EST - 2 years ago

Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer

Dec 12, 2022, 11:45 AM EST - 2 years ago

Newman Ferrara LLP Announces Corporate Governance Investigations of Instil Bio, Inc. (TIL)

Dec 8, 2022, 7:00 AM EST - 2 years ago

Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce

Nov 14, 2022, 4:07 PM EST - 2 years ago

Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 8, 2022, 6:13 PM EST - 2 years ago

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

Nov 8, 2022, 7:00 AM EST - 2 years ago

Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 7, 2022, 8:59 AM EST - 2 years ago

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

Nov 2, 2022, 9:39 AM EDT - 3 years ago

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

Nov 1, 2022, 5:30 PM EDT - 3 years ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Instil Bio, Inc. (TIL) on Behalf of Investors

Nov 1, 2022, 1:33 PM EDT - 3 years ago

The Law Offices of Frank R. Cruz Announces Investigation of Instil Bio, Inc. (TIL) on Behalf of Investors

Nov 1, 2022, 10:50 AM EDT - 3 years ago

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

Oct 31, 2022, 8:52 AM EDT - 3 years ago

Instil Bio's stock falls 35% after disclosing the cell therapy company paused enrollment in clinical trials

Oct 31, 2022, 7:00 AM EDT - 3 years ago

Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing

Magic8BallResponse Jul. 31 at 1:12 PM

$TIL Due for an upgrade

0 · Reply

OpenOutcrier Jul. 31 at 11:37 AM

0 · Reply

BigSqueezeComing Jul. 31 at 10:39 AM

$TIL ImmuneOnco expects to present updated safety and efficacy data at a forthcoming medical conference. Plans include advancing IMM2510/AXN‑2510 into Phase 3 studies in China.

0 · Reply

BigSqueezeComing Jul. 31 at 10:38 AM

0 · Reply

BigSqueezeComing Jul. 31 at 10:38 AM

$TIL took profit

0 · Reply

BigSqueezeComing Jul. 31 at 10:36 AM

$TIL going higher

0 · Reply

BigSqueezeComing Jul. 31 at 10:19 AM

$TIL pt 30+

0 · Reply

BigSqueezeComing Jul. 31 at 10:10 AM

0 · Reply

NVDAMillionaire Jul. 29 at 7:18 PM

0 · Reply

Doozio Jul. 27 at 9:38 PM

Wait $TIL the huckleberries arrive n they give a 🪧 during 🐒🍌🧠⏰♾️

0 · Reply

Power2k Jul. 25 at 5:42 PM

$TIL = 0.2B and $SMMT = 20B. We are 1/100 of Summit.

0 · Reply

Bigmal1 Jul. 24 at 5:25 PM

$TIL $100 minimum

0 · Reply

Doozio Jul. 23 at 4:50 PM

$ELTX just wait $TIL they BRAG 🐒🍌🧠⏰♾️

0 · Reply

StockScanners Jul. 22 at 7:41 PM

$TIL Unusual Volume,

0 · Reply

Doinaw Jul. 11 at 2:51 PM

$INKT next $TIL i’m in @40$ and out 78$

0 · Reply

2nd_mind Jul. 9 at 1:11 PM

$TIL someones told me about this stocks. Let's printing 💲💲

0 · Reply

Power2k Jul. 7 at 1:27 PM

$TIL $SMMT is worth 18b while we are at just 0.18B with a potential best-in-class PD-(L)1/VEGF bi-specific Ab? $AZN Why not buying Instil Bio straight out for 10-15B and call it a day? $BNTX

1 · Reply

Jonita Jul. 3 at 4:42 PM

$TIL 💪💪💪

0 · Reply

patb99 Jul. 3 at 3:12 PM

$TIL VWAP under 28$

0 · Reply

Bigmal1 Jul. 2 at 12:57 PM

$TIL great news… where’s the love

1 · Reply

BigSqueezeComing Jul. 2 at 10:37 AM

$TIL added more. pm gapper

0 · Reply

BigSqueezeComing Jul. 2 at 10:28 AM

$TIL pm gapper Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors By Instil Bio | July 02, 2025, 6:00 AM

0 · Reply

Market Cap	183.55M
Revenue (ttm)	0.00
Net Income (ttm)	-74.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.58

Volume	120,400
Avg Vol	317,008
Day's Range	N/A - N/A
Shares Out	6.56M
Stochastic %K	77%
Beta	2.16
Analysts	Strong Sell
Price Target	$118.67